AbbVie Inc. $ABBV Stock: Phoenix Financial Ltd. Raises Position

Phoenix Financial Ltd. increased its position in AbbVie Inc. (NYSE:ABBV) by 10.1% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 52,244 shares of the company’s stock after purchasing an additional 4,803 shares during the period. Phoenix Financial Ltd.’s holdings in AbbVie were worth $13,667,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Financial Freedom LLC acquired a new stake in AbbVie during the 3rd quarter valued at $29,000. Burk Holdings LLC purchased a new stake in shares of AbbVie in the second quarter valued at $30,000. Marquette Asset Management LLC boosted its position in shares of AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after buying an additional 48 shares during the period. Principia Wealth Advisory LLC boosted its position in shares of AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after buying an additional 44 shares during the period. Finally, IMG Wealth Management Inc. boosted its position in shares of AbbVie by 3,060.0% in the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after buying an additional 153 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on ABBV. Rothschild & Co Redburn upped their price target on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. HSBC raised their price objective on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Oppenheimer lifted their target price on AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. Sanford C. Bernstein reiterated a “market perform” rating and issued a $275.00 target price on shares of AbbVie in a report on Monday, November 2nd. Finally, Guggenheim upped their target price on AbbVie from $288.00 to $322.00 and gave the company a “buy” rating in a report on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $297.46.

More AbbVie News

Here’s some of the latest news about ABBV:

• Positive Sentiment: AbbVie’s immunology sales grew 16.6% in the third quarter, led by Skyrizi and Rinvoq. Their momentum is helping lift sales expectations for 2026, although Humira continues to decline. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Positive Sentiment: AbbVie licensed Nxera Pharma’s EP4 agonist program for inflammatory bowel disease. The deal adds a potential pipeline asset, though its milestones depend on future development and other conditions. AbbVie Deal Altering the Investment Case for Nxera Pharma
• Negative Sentiment: EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. The sale could weigh on sentiment, though the filing did not state a reason. AbbVie EVP Sells $11,925,738.40 in Stock

Insider Buying and Selling

In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the company’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the transaction, the executive vice president directly owned 83,171 shares of the company’s stock, valued at $24,419,005.60. This represents a 32.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by company insiders.

AbbVie Stock Up 0.2%

Shares of NYSE:ABBV traded up $0.73 during trading on Friday, reaching $295.18. 3,259,920 shares of the company traded hands, compared to its average volume of 5,279,493. The firm has a fifty day simple moving average of $275.51 and a 200 day simple moving average of $240.91. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $302.93. The firm has a market cap of $521.76 billion, a P/E ratio of 50.81, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The business had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same period in the prior year, the business posted $1.86 earnings per share. AbbVie’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, research analysts anticipate that AbbVie Inc. will post 13.98 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be paid a $1.82 dividend. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. This is an increase from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. AbbVie’s dividend payout ratio is presently 125.30%.

AbbVie Company Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.